Mandate

Vinge advises the Port of Gothenburg in the divestment of their container terminal

October 11, 2011

APM Terminals has acquired Skandia Container Terminal AB and will take over the operation of the container terminal in the Port of Gothenburg. Skandia Container Terminal AB was acquired from Göteborg Port Operation AB, a company controlled by the City of Gothenburg. In connection with the transaction, a concession agreement will be entered into concerning the operation of the terminal and related infrastructure. The acquisition is subject to approval of the relevant competition authorities.The transaction was the last of three in relation to the privatization process of the terminal operations in the Port of Gothenburg. The other two terminals, i.e. the ro/ro- and the car terminal respectively, were sold during 2010 and 2011. The Port of Gothenburg is by far the largest port in the Nordic region and the container terminal handles approximately 800,000 containers per year.

Vinge has advised Göteborg Port Operation AB and the Port of Gothenburg throughout the privatization process. The firm’s team was led by Fredrik Sonander and included Charlotte Forssander and Lisa Askbrink, as well as a number of other co-workers from the practice groups M&A, Shipping, Employment and Pensions, Real Estate and Environment.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026